PHARMAGENESIS’ PG2 PASSES CLINICAL TRIALS IN CHINA

Adjunct Cancer Therapy Drug Restores Blood Cells During Chemotherapy

BEIJING - March 19, 2001 - PG2, a plant-derived hematopoiesis enhancer developed by Pharmagenesis, Inc. that restores blood cells after destruction of bone marrow cells induced by chemotherapy, has successfully passed clinical trials in China.

PG2, an adjunct to cancer therapy to improve patients’ quality of life, proved more efficient in stimulating growth of key blood cell lines during chemotherapy than G-CSF, the positive control product used in the trials.

A Chinese New Drug Class II, PG2 was studied in Western-style clinical trials at the pharmacology unit of Gueng An Men Hospital in Beijing, the most widely recognized traditional Chinese medicine hospital, and five other hospitals endorsed by China’s Ministry of Public Health located in China provinces.

Chinese clinical trials are regulated by the State Drug Administration (SDA), which is modeled after the U.S. Food and Drug Administration (FDA).  The SDA employs stringent regulations similar to those used in U.S. drug trials.

“The trials prove patients who experience blood cell depletion while undergoing chemotherapy can benefit from PG2,” Nicolas Druz, CEO, Pharmagenesis, said.  “The results substantiate our vision that extracts from plants used in traditional Chinese medicine are a reliable and cost-efficient source for the development of new ethical drugs.”

PG2 will be sold in China once authorization is granted.

 

About Pharmagenesis, Inc.

Pharmagenesis, Inc. develops anticancer therapies and treatments for cancer therapy-related bone-marrow suppression and for the management of transplant rejection.  The privately held company focuses on developing ethical pharmaceuticals from purified extracts of plants that have been employed in traditional Chinese medicine for more than 4,000 years.  Efficacy is validated by clinical trials conforming to standards of appropriate government regulatory agencies.  Pharmaceuticals developed and/or licensed by the company are being commercialized initially in the high-growth markets of China and Taiwan.

Pharmagenesis’ corporate headquarters and R & D facility, employing cutting-edge Western medical research techniques, are located in Palo Alto, Calif.  Pharmagenesis also has operations in Beijing and Taipei.

 

May 22, 2001 ] April 2, 2001 ] April 16, 2001 ] [ Mar 19, 2001 ] Feb 23, 2001 ] Feb 2, 2001 ] Dec, 2000 ]

Home ] SAB ] Milestones ] Business Dev ] Press Releases ]